Shares of Tatva Chintan Pharma Chem zoomed 17 per cent to Rs 2,488.90 on the BSE in Monday’s intraday commerce after the corporate reported a sturdy set of numbers for the quarter ended September 2021 (Q2FY22), on again of upper income. The inventory of the specialty chemical substances was buying and selling at its highest stage since its itemizing on July 29, 2021.
For Q2FY22, Tatva Chintan’s consolidated web revenue jumped over nine-fold to Rs 32.41 crore as in opposition to Rs 3.56 crore in Q2FY21. Income from operations throughout the quarter greater than doubled to Rs 123.62 crore from Rs 60.04 crore within the corresponding quarter of earlier fiscal. The corporate’s, earnings earlier than curiosity, tax, depreciation and amortization (ebitda) margin improved to 31.3 per cent from 13.85 per cent.
Tatva Chintan is a specialty chemical substances manufacturing firm engaged within the manufacture of a various portfolio of construction directing brokers (SDAs), part switch catalysts (PTCs), electrolyte salts for tremendous capacitor batteries and pharmaceutical and agrochemical intermediates and different specialty chemical substances (PASC).
Tatva Chintan had made a stellar inventory market debut, with a whopping 95 per cent premium itemizing over its situation value of Rs 1,083 per share on the BSE. With at this time’s rally, the inventory has zoomed 130 per cent from its situation value.
The corporate is working in a really area of interest section with nice merchandise that present these advantages are witnessing sturdy demand in India and globally. The corporate intends to play an incredible function within the worth chain by increasing its portfolio to cater to clients throughout various sectors and geographies, whereas persevering with to strengthen the present product portfolio by leveraging its huge expertise and technical capabilities.
The corporate believes that enlargement of R&D competencies will present it with long-term progress alternatives in capturing rising demand and evolving buyer necessities. In the direction of this, it plans to deploy new-age applied sciences for product growth and processes to enhance productiveness, high quality, and value effectiveness.
“Continued R&D investments and concentrate on high quality and well timed supply will assist enhance the pockets share and product portfolio with present clients. Additional, the Firm plans to leverage its huge gross sales and advertising and marketing community, complete product portfolio, and trade standing to broaden buyer base,” Tatva Chintan mentioned in monetary yr 2020-21 (FY21) annual report.
Together with this, the Firm additionally intends so as to add capability in a phased method to make sure optimum utilization and meet the anticipated enhance within the demand for its merchandise, which can allow it to produce to rising markets extra effectively and drive profitability, the corporate mentioned.
At 11:05 am; the inventory was buying and selling 10 per cent greater at Rs 2,346 on the BSE, as in comparison with 0.07 per cent rise within the S&P BSE Sensex. The buying and selling volumes on the counter nearly-doubled with a mixed 363,000 shares altering palms on the NSE and BSE.